Short-term outcomes of neoadjuvant immunotherapy combined with minimally invasive McKeown esophagectomy for locally advanced thoracic esophageal squamous cell carcinoma: A retrospective cohort study
- VernacularTitle:新辅助免疫治疗联合微创McKeown术治疗局部晚期食管鳞癌近期结果的回顾性队列研究
- Author:
Hanran WU
1
;
Changqing LIU
1
;
Xiaohui SUN
1
;
Jieyong TIAN
1
;
Xinyu MEI
1
;
Meiqing XU
1
;
Mingran XIE
1
Author Information
1. Department of Thoracic Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
thoracoscopes;
esophagectomy;
cervical anastomosis;
neoadjuvant therapy
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(12):1767-1774
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility, safety, and short-term efficacy of minimally invasive McKeown esophagectomy (MIME) in patients with locally advanced thoracic esophageal squamous cell carcinoma (TESCC) after neoadjuvant immunotherapy. Methods The clinical data of the patients with locally advanced TESCC in the First Affiliated Hospital of University of Science and Technology of China from July 2022 to March 2023 were restrospectively analyzed. They were divided into a neoadjuvant immunotherapy (NI) group and a non-neoadjuvant immunotherapy (NNI) group according to different preoperative neoadjuvant therapy. The perioperative clinical data and 3-month follow-up data were compared between the two groups. Results A total of 47 patients were collected, including 31 males and 16 females with a mean age of (67.57±7.64) years. There were 29 patients in the NI group and 18 patients in the NNI group. There were no statistical differences in baseline data, perioperative complications, short-term complications, surgical time, intraoperative bleeding, postoperative adjuvant therapy, metastasis/recurrence within 3 months, R0 resection rate, postoperative pathological staging decline, or College of American Pathologists (CAP) tumor regression grade between the two groups (P＞0.05). Conclusion Neoadjuvant immunotherapy combined with minimally invasive McKeown esophagectomy can be safely and effectively performed for patients with locally advanced TESCC without increasing operation time, intraoperative blood loss and perioperative complications.
